Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Jennifer Anne McLean
Modelling Ponatinib Resistance in Tyrosine Kinase Inhibitor-Naïve and Dasatinib Resistant BCR-ABL1+ Cell Lines
Oncotarget
Oncology
Related publications
Gold Nanoparticles for BCR-ABL1 Gene Silencing: Improving Tyrosine Kinase Inhibitor Efficacy in Chronic Myeloid Leukemia
Molecular Therapy - Nucleic Acids
Drug Discovery
Molecular Medicine
Tyrosine Kinase Fusion Genes in Pediatric BCR-ABL1-like Acute Lymphoblastic Leukemia
Oncotarget
Oncology
The Impact of BCR-ABL1 Transcript Type on Tyrosine Kinase Inhibitor Responses and Outcomes in Patients With Chronic Myeloid Leukemia
Cancer
Cancer Research
Oncology
Differential Genomics and Transcriptomics Between Tyrosine Kinase Inhibitor-Sensitive and -Resistant BCR-ABL-dependent Chronic Myeloid Leukemia
Oncotarget
Oncology
Genetic Alterations in Epidermal Growth Factor Receptor‑tyrosine Kinase Inhibitor‑na�ve Non‑small Cell Lung Carcinoma
Oncology Letters
Cancer Research
Oncology
BCR-ABL Tyrosine Kinase
Science-Business eXchange
The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model
Frontiers in Cardiovascular Medicine
Cardiovascular Medicine
Cardiology
BCR-ABL1 and Beyond
Pathology
Forensic Medicine
Pathology
The Tyrosine Kinase Inhibitor Dasatinib Reduces the Growth of Intracellular Mycobacterium Tuberculosis Despite Impairing T-Cell Function
European Journal of Immunology
Allergy
Immunology
